Table 2.
Overview of HBM4EU Aligned Studies and bilateral data sources.
| Data Provider | Year of Sampling |
No. Participants |
Mean Age (Years) |
Sex (Perc. Male) |
Mean AAMA in µg/L |
Mean GAMA in µg/L |
|---|---|---|---|---|---|---|
| EPIUD NAC II (IT1) | 2014 | ns 18 | 7.0 | 0 | 64.85 | 24.73 |
| EPIUD NAC II (IT2) | 2015 | ns 132 | 7.2 | 52.3 | 84.58 | 31.57 |
| EPIUD NAC II (IT3) | 2016 | ns 147 | 7.0 | 55.1 | 94.58 | 30.46 |
| UBA GerES V (DE1) | 2015 | ns 852 | 10.3 | 50.2 | 90.7 | 17.57 |
| UBA GerES V (DE2) | 2016 | ns 849 | 10.3 | 47.1 | 88.24 | 16.43 |
| UBA GerES V (DE3) | 2017 | ns 517 | 10.3 | 49.7 | 102.52 | 20.52 |
| NIPH NEB II (NO) | 2016 | ns 289 | 9.8 | 52.9 | 75.92 | 11.13 |
| ANSP ESTEBAN (FR4) | 2014 | ns 55 | 8.5 | 49.1 | 92.6 | 12.15 |
| ANSP ESTEBAN (FR5) | 2015 | ns 208 | 8.9 | 52.6 | 85.52 | 11.37 |
| ANSP ESTEBAN (FR6) | 2016 | ns 37 | 8.9 | 54.0 | 82.97 | 11.59 |
| UI Diet-HBM (IS1) | 2019 | ns 289 s 6 |
31.6 | 53.6 | 70.88 146.91 |
9.87 19.24 |
| UI Diet-HBM (IS2) | 2020 | ns 154 s 12 |
30.6 | 41.5 | 77.57 158.40 |
12.18 22.89 |
| INSA INSEF-ExpoQuim (PT1) | 2019 | ns 177 s 67 |
34.5 | 39.0 | 84.32 232.46 |
29.07 52.07 |
| INSA INSEF-ExpoQuim (PT2) | 2020 | ns 37 s 12 |
34.7 | 40.5 | 90.85 136.95 |
27.96 50.62 |
| LNS Oriscav-Lux2 (LU1) | 2016 | ns 34 s 7 |
33.3 | 41.2 | 72.48 263.24 |
13.32 34.71 |
| LNS Oriscav-Lux2 (LU2) | 2017 | ns 123 s 25 |
33.5 | 48.0 | 68.42 184.85 |
14.44 28.47 |
| LNS Oriscav-Lux2 (LU3) | 2018 | ns 12 | 33.7 | 58.3 | 57.93 | 11.69 |
| ANSP ESTEBAN (FR1) | 2014 | ns 36 s 27 |
31.4 | 50 | 68.25 278.72 |
8.2 26.15 |
| ANSP ESTEBAN (FR2) | 2015 | ns 138 s 64 |
32.5 | 39.9 | 85.94 304.32 |
10.35 29.29 |
| ANSP ESTEBAN (FR3) | 2016 | ns 23 s 10 |
34.0 | 34.8 | 89.22 222.21 |
11.43 21.42 |
AAMA: N-acetyl-S-(carbamoylethyl)-l-cysteine), GAMA: N-acetyl-S-(1-carbamoyl-2-hydroxyethyl)-l-cysteine), non-smoker: n.s., smoker: s.